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Abstract 
In a French national cohort of unaffected females carriers/non-carriers of a BRCA1/2 
mutation, long-term preventive strategies and breast/ovarian cancer risk perceptions were 
followed up to 5 years after test result disclosure, using self-administered questionnaires. . 
Response rate was 74%. Carriers (N=101) were younger (average age ± SD = 37±10) than 
non-carriers (N=145; 42 ± 12). There were four management strategies that comprised 
88% of the decisions made by the unaffected carriers: 50% opted for breast surveillance 
alone, based on either  Magnetic Resonance Imaging (MRI) and other imaging (31%) or  
mammography alone  (19%); 38% opted for either Risk Reducing Salpingo-Oophorectomy 
(RRSO) and breast surveillance, based on MRI and other imaging (28%) or mammography 
alone  (10%). The other three strategies were: Risk Reducing Mastectomy (RRM) and 
RRSO (5%), RRM alone (2%), and neither RRM/RRSO nor surveillance (6%). The results 
obtained for various age-groups are presented here.  Non-carriers often opted for screening 
despite their low cancer risk. Result disclosure increased carriers’ short-term high 
breast/ovarian cancer risk perceptions (p≤0.01) and decreased non-carriers’ short- and 
long-term perceptions (p<0.001). During follow-up, high breast cancer risk perceptions 
increased with time among those who had no RRM and decreased in the opposite case; 
high ovarian cancer risk perceptions increased further with time among those who had no 
RRSO and decreased in the opposite case; RRSO did not affect breast cancer risk 
perceptions. Informed decision-making involves letting women know whether opting for 
RRSO and breast MRI surveillance is as effective in terms of survival as RRM and RRSO.  
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Introduction 
 
Many surveys have addressed the short-term impact of BRCA1/2 genetic mutation testing 
on perceived risks and behavioural outcomes in heterogeneous samples 1,2. In three 
prospective studies, unaffected women were followed for two 3,4 and 3 years  5 after 
disclosure of their test results  in a routine context, and only one study has followed a 
selected sample of 23 women (21 of whom underwent risk reducing mastectomy) up to 5 
years 6. The largest samples of unaffected BRCA1/2 carriers studied so far included 53 5 
and 68 women 3. In these studies, the behaviour of cohorts of female non-carriers from 
BRCA1/2 families was followed simultaneously. Another study was specifically designed to 
describe the behaviour of this group 7. A large Canadian survey retrospectively selected a 
large number of unaffected BRCA1/2 carriers (N=342) and followed their preventive 
behaviours until 4 years after their test results on average 8.  
 
A decrease in breast and ovarian cancer risk perception has been described in non-carriers 
12 months after genetic testing, and a lower breast cancer risk perception in non-carriers 
compared to carriers. Only one study has shown that carriers’ risk perceptions were higher 
six months after disclosure than before testing 9. . It has been concluded that risk 
perception decreases with time 2.   
 
Behavioural outcomes have been described as rates of surveillance or prophylactic surgery 
undergone by carriers/non-carriers: Risk Reducing Mastectomy (RRM) is undergone by 
most  carriers in the Netherlands (55%) 3 and Denmak 10, in a third of the UK series studied 
(34%) 5 and less frequently elsewhere 4,8,11. Although the rates of Risk Reducing Salpingo-
Oophorectomy (RRSO) reported were higher, most of these studies made no reference to 
the age at which the intervention should be proposed according to current guidelines. Rates 
of compliance with mammographic surveillance have been studied in women who were 
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screened for two years after test disclosure, but no information is available about the 
number of investigations carried out. Women’s decision-making processes have been 
described individually but no information has been published so far about the follow-up of 
various age-groups or about the whole series of decisions on which their medical 
management depends. In particular, the uptake of Magnetic Resonance Imaging (MRI) by 
these cohorts as a means of surveillance has not yet been documented. 
 
The aim of this study was first to describe the sequences of preventive decisions made by 
women up to five years after disclosure of their test results and the surveillance/surgical 
options chosen by various age-groups. It was also proposed to examine the impact of 
BRCA1/2 genetic testing and preventive strategies on these women’s cancer risk 
perceptions with time. Women included in this prospective national study were unaffected 
carriers/non-carriers who underwent a baseline assessment before test result disclosure 
and regular follow-up for the next 5 years.  BRCA1/2 carriers’ and non-carriers’ long-term 
risk perceptions were expected to depend not only on their carrier/non-carrier status but 
also on the series of preventive strategies chosen. 
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Material and Methods 
Population   
In the framework of the ongoing French “Genepso” project managed by the French Cancer 
Genetic Network, BRCA1/2 carriers attending 29 participating centres were registered 
between 2000 and 2006. Only epidemiological data have been published so far on this 
cohort, although other studies are under way 12,13 14. In the present study on “Psychosocial 
and Preventive Behaviour”, non-carriers from families where these BRCA1/2 mutations had 
been identified were included along with carriers.  
 
The behavioural characteristics of unaffected female carriers and non-carriers of the 
deleterious BRCA1/2 mutation were therefore compared. For this purpose, all the cases 
who reached the five year follow-up endpoint were selected. In France, the cost of cancer 
genetic consultations, BRCA1/2 testing and any subsequent medical management of 
people at risk is covered by the national healthcare system. 
 
Questionnaires 
Process  
 Consultees were asked to complete six self-administered questionnaires. The first 
questionnaire, which was designed to collect baseline information, was completed before 
disclosure of the BRCA1/2 genetic test results by all the women. The women who agreed to 
participate to the follow-up were then given a second questionnaire at disclosure, to be 
returned fifteen days later. The 4 other questionnaires were mailed to the women’s  homes 
6 months, one year, 2 years and 5 years later. If no answer had been received one month 
after mailing a questionnaire, a reminder letter and a copy of the questionnaire were sent 
out. All the questionnaires were mailed back to the coordinating centre. The procedure 
used was approved by the "Comité National Informatique et Libertés".  
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The cancer geneticists also completed a questionnaire describing the women’s family and 
medical characteristics at inclusion and follow-up. 
 
Variables  
 
Preventive behavior 
At the five-year follow-up, information was collected about the occurrence, frequency and 
number of mammography, MRI, and ovarian ultrasound examinations undergone during the 
previous three years. The same questions were also asked about mammography and 
ovarian ultrasound at the one and two year follow-ups but the question about MRI was 
asked only at the five-year follow-up, since the medical guidelines only recommended this 
type of investigation for the first time in 2004 15,16. The occurrence of prophylactic surgery 
was cross-checked with the medical records. Details about prophylactic surgery (RRM, 
RRSO) were collected prior to disclosure of results and then again at the one-, two- and 
five- year follows. Baseline preventive behaviours had been asked in the pre-disclosure 
questionnaire. 
 
Perception of personal risk of cancer.  
Perception of the personal risk of developing breast cancer was measured on a six-point 
Likert scale before disclosure and at follow-up by asking the same question: “Do you think 
your risk of developing breast cancer is: “very high” “high” “moderate” “low” “very low” “don’t 
know”. The same questions were asked about respondents’ perception of their risk of 
developing ovarian cancer and about their perception of the risk of developing cancer of 
other kinds. 
 
 
Socio-demographic, psychological and medical characteristics  
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Socio-demographic variables such as age, number of children, level of education, 
occupation, prior preventive behaviour and psychological variables were collected at 
baseline for all the women included and updated during follow-up. 
The medical characteristics included the number of first and second degree relatives 
affected with breast/ovarian cancer at inclusion, and the deleterious BRCA1/2 mutation 
involved. 
 
Statistical Analysis 
Chi-square tests, t-tests, and ANOVA were used to make univariate comparisons on 
categorical and continuous variables. McNemar’s chi-square tests were used to compare 
respondents’ cancer risk perceptions at different times. The level of statistical significance 
(α error) was taken to be p≤0.05. 
 
 Data analysis was conducted in 3 stages.  
- To check how representative the final sample was after 5 years, the respondents’ 
and non-respondents’ baseline sociodemographic, psychosocial and medical 
characteristics were compared.  
- The preventive strategies used by carriers/non carriers were recorded at the 5-year 
follow-up. They are presented in a decision tree and the two groups were then 
compared after stratifying the results by age-group. The sequences of preventive 
options chosen by BRCA1/2 carriers were analysed at the 5-year follow-up.  
- High/very high breast, ovarian, and other cancer risk perceptions documented at 
various times were studied, depending on the preventive strategies chosen (or not)  
by carriers/non carriers. High and very high risk perception levels were grouped 
together and denoted “high” perceptions. 
The Statistical Package for Social Science (SPSS/PC Released 17.0) was used to 
perform all the statistical analyses. 
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RESULTS 
Respondents vs non respondents 
Among the 345 women who completed the first questionnaire before test result disclosure 
and who should have reached the five years follow-up endpoint, 14 were excluded because 
they had developed breast cancer (n=12) or ovarian cancer (n=2) by the 5th year of follow-
up; all 14 were BRCA1/2 mutation carriers. Among the unaffected women at five years 
(N=331), 246 (74%) completed all five questionnaires and were included in this analysis.  
Respondents and non-respondents did not differ significantly in their baseline 
sociodemographic, psychological or medical characteristics. However, respondents had 
reported doing Breast Self Examination significantly more frequently than non- respondents 
(p≤0.05) in the baseline questionnaire. 
 
Sample Characteristics  
Among these 246 women, 41% (N=101) were carriers of a familial BRCA1/2 mutation, 
whereas 59% (N=145) were non-carriers. The mean age of the BRCA1/2 carriers at the 
time of disclosure was 37.2 years (SD=10.2), which differed significantly from that of the 
non-carriers (41.7 ± 11.8) (±SD) (p=0.002). The level of education, marital status and 
number of children did not differ significantly between BRCA1/2 mutation carriers and  non-
carriers. Medical characteristics such as the number of first degree relatives affected were 
also similar  between carriers and non-carriers. Respondents’ characteristics are given in 
Table 1. The 246 respondents belonged to 166 different families: 68.1% (n=113) of these 
families were represented in the sample by a single woman, whereas the remaining, 31.9% 
(n=53) were represented by several members, numbering 2.5 on average (median 2; range 
2 to 6). Among the 18 centres who reported carriers, 3 had reported 56.5% of the cases 
analysed (n=57) and 15 had reported the remaining 44.5% (n=44). The average number of 
carriers by centre was 5.6 (range 1-31). 
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Preventive strategies in mutation carriers/non-carriers after disclosure of the 
BRCA1/2 test results 
Carriers (n=101): a decision tree was drawn up describing the seven strategies 
documented at the five-year follow-up, including prophylactic surgery and breast imaging 
(Figure 1). Since Transvaginal Ultrasound is not thought to be an effective 17 means of 
improving ovarian cancer prognosis and is not officially recommended in France 15,16, it was 
not included in these decision trees but noted separately.  Four strategies accounted for 
88% of the preventive options chosen by the carriers at the end of the five year follow-up: 
50% had opted for breast surveillance alone, based on either Magnetic Resonance Imaging 
(MRI) and other imaging methods in 31% of cases (n=31; strategy S5), or based on 
mammography alone in 19% (n=19; S6); 38% had opted for Risk Reducing Salpingo-
Oophorectomy and breast surveillance based on MRI and/or other imaging methods in 28% 
of cases (n=28; S3) or mammography alone in 10% (n=10; S4). The other three strategies 
documented were Risk Reducing Mastectomy (RRM) and RRSO (5%) (n=5; S1), RRM 
alone (n=2; 2%; S2), and neither RRM/RRSO nor surveillance (n=6; 6%; S7). One 45-year 
old woman who had opted for S2 planned to undergo RRSO 5 weeks after completing the 
final questionnaire; the other one was 48 years old and had no family history of ovarian 
cancer. In the S7 group, 2 women were under 30 years of age; the others were aged 
between 31 and 39.  These strategies were stratified by age, above and below 40 years of 
age, as shown in figures 2a and 2b. 
 
Among the carriers, RRM was undergone by 7%, and this option was not correlated with 
the women’s age. RRSO was undergone by 43% of the carriers,  and this option was 
chosen significantly more frequently with age (p<0.001): the rate of uptake increased from 
18% in the 30- to 39 year -olds to 65% in those ≥ 40 years of age. During the last 3 years, 
the women underwent 2.8 mammograms on average and 1.7 MRI on average (table 2). 
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MRI was undergone by 63% (in 59/94 cases without RRM), and no correlations were 
observed with age in this respect. A high rate of ovarian ultrasound screening was still 
observed during the last 3 years among those who underwent no RRSO. The results 
obtained on each age-group are presented in Table 2.    
Non-carriers (n=145): No RRM was performed on non-carriers after disclosure of the 
results, but 3 Salpingo-Oophorectomies were undergone by non-carriers for other medical 
reasons (fibroma or cystic ovaries) (Table 2). 53% of the women aged between 30 and 39 
years (20% of the <30 age-group)  reported at the final follow-up that they had continued to 
undergo annual or two-yearly mammography during the previous 3 years; only 7 (4.8%) 
had undergone MRI; 43.2% stated that they had undergone an ovarian ultrasound 
examination during the last 3 years.  
 
High perceptions of breast/ovarian cancer risks versus  preventive strategies and 
mutation carrier/non carrier status.   Disclosure of the BRCA1/2 status significantly 
affected the carriers and non carriers’ high perceptions of breast/ovarian cancer risks. 
Among  the carriers, it significantly increased   the proportion of carriers with high/very high 
breast cancer risk perceptions (from 63% before disclosure to 81% 6 months after 
disclosure, McNemar’s chi-square, p=0.016) and some carriers’ high ovarian cancer risk 
perceptions (from 42% before disclosure to 62% 6 months after disclosure, McNemar’s chi-
square p=0.007); whereas it decreased high breast cancer risk perceptions (N=145) (figure 
3; p<0.001) and high ovarian cancer risk perceptions  (figure 4; p<0.001) in non-carriers. 
High perception of other cancer risks was relatively infrequent and not affected by 
disclosure (12.1% and 9.5% before disclosure and 6 months after disclosure, respectively, 
McNemar’s chi-square p=0.248 and 11.2%, 7.9%, and 15.5% after 1, 2 and 5 years, 
respectively). 
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All those who eventually opted for RRM by the 5th year of follow-up (Strategies S1 and S2 
in figure 1; n=7) had high breast cancer risk perceptions before disclosure; these high 
perceptions decreased with time after disclosure and after undergoing RRM (Figure 3). 
High breast cancer risk perceptions increased steadily with time among  all the other 
carriers, regardless of whether or not they opted for Risk Reducing Salpingo-Oophorectomy 
(Strategies S3 and S4 in figure 1; n=38) or not (Strategies S5-S7, figure 1; n=56).   
 
 High ovarian cancer risk perceptions with time showed  the same pattern as with  breast 
cancer.  Among carriers who did not opt for RRM, those who opted for RRSO (Strategies 
S3-S4 in Figure 1) had higher ovarian cancer risk perceptions before disclosure than those 
who  did not (Figure 4; p=0.014). Between 6 and 60 months after disclosure of the results,  
these high perceptions decreased significantly  after  RRSO (McNemar; p=0.002), whereas 
a significant increase (McNemar; p=0.049) occurred among  those who did not opt for 
surgery.  
 
Discussion 
 
This is the first time the preventive strategies used by a French national cohort of 
unaffected female BRCA1/2 carriers and non carriers have been documented for five years 
after routine genetic test result disclosure. The preventive strategies reported by 
respondents  five years after disclosure show that in France, regular MRI surveillance 
(along with other breast imaging methods) is the most frequently preferred strategy among 
unaffected female BRCA1/2 carriers under 40 years of age, whereas  RRSO tends to be 
combined  with regular MRI breast imaging among older women (Figures 2a, 2b). When the 
decision to undergo RRM has been made, RRSO is generally undergone as well (Figure 1). 
Trans-vaginal ultrasound investigations were undergone regularly by carriers without 
RRSO, and non-carriers appeared to favour opting for screening despite their low cancer 
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risk (table 2). In France this screening is possible when prescribed by a medical 
practitioner. High breast/ovarian cancer risk perceptions were significantly affected in both 
the short and long term among carriers and non-carriers alike. In the long run, high breast 
cancer risk perceptions increased steadily with time among those without RRM (and 
decreased among the small sample with RRM), and a similar pattern  was observed in the 
case of  ovarian cancer risk perception and RRSO. RRSO had no effect on breast cancer 
risk perceptions. 
 
It was reported some time ago that there is little enthusiasm in France for RRM, either 
among health professionals or women attending cancer genetic clinics 18,19. The present 
results confirm the reluctance previously observed about these issues, although the rate of 
uptake of RRSO in France is comparable to that of other countries in the relevant age-
groups. Health professionals in France seem to expect MRI to be a highly effective means 
of detecting early forms of breast cancer, resulting in a good prognosis, whereas those in 
other countries prefer the highly effective surgical strategies available. It would be 
interesting to know the survival rates associated with each combination of preventive 
strategies, which would help to give women all the information required for their decision-
making to be autonomous and well-informed.  
 
It is worth discussing  the increase observed here in the high  breast/ovarian cancer risk 
perceptions of those who did not undergo risk reducing surgery, as well as the fact that 
RRSO did not decrease high breast cancer risk perceptions although this intervention is 
known to significantly decrease the risk of breast cancer 20. Finch et al. 21 retrospectively 
assessed the impact of genetic counseling and RRSO on breast and ovarian cancer risk 
knowledge and concluded that most women accurately perceived their breast cancer risks. 
Our results mean either that the information was not delivered by health care professionals 
or that RRSO had no impact on a priori lay beliefs about breast cancer risks. Cancer risk 
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perception is a complex and subjective issue, since  risk perception seems to have nothing 
to do with “risk knowledge”. Risk perception is known to determine behavior, whereas 
people’s “risk knowledge” is not predictive of their health-related behavior 22. Risk 
perception may decrease when the main target organ of cancer has been removed 
surgically, whereas the situation is not the same when another organ is taken out, and the 
preventive action obtained through the suppression of hormonal effect. Previous studies 
have shown that women’s psychological distress decreases after undergoing prophylactic 
mastectomy 23, and that their fear of developing cancer also decreases, 6 which is similar to 
what occurs with high risk perception or affective risk perception 24 . However, other authors 
have reported that the levels of distress are still high after these interventions, especially 
RRSO 25, possibly because these women’s perception of the remaining risk of breast 
cancer has not changed significantly.  
 
Our study had several limitations. First, respondents always differ from non-respondents, 
even if they have the same baseline characteristics.  Only baseline Breast Self Examination 
practices differed here between respondents and non-respondents; therefore we must 
remember that our results may not be completely representative of the whole cohort or of 
the whole French population of BRCA1/2 carriers, although we benefited from the 
advantages  of multicentre, nation-wide recruitment. Secondly, the same bias occurred as 
in previous studies, since following the same group of people with questionnaires may 
affect their spontaneous decisions during follow-up and hence the methods of surveillance 
and prevention they choose. We also have to take the time-factor into account, since 
preventive recommendations evolve with time and  while the people in this study  were 
being tested,  new preventive recommendations were issued in 2004, especially as regards 
prophylactic surgery, which was more strongly recommended 16 than previously 15.  
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In conclusion, women’s cancer risk perceptions five years after disclosure of their BRCA1/2 
status depend on decisions about preventive interventions more than simply on the 
outcomes  of mutation tests . Women need to know more these days about the probability 
of  survival associated with all the  strategies available,  and in particular whether opting for 
RRSO and breast MRI surveillance is likely to be as effective as undergoing both RRM and 
RRSO in terms of survival.   
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Figure Legends 
 
Figure 1: Preventive management strategies observed in BRCA1/2 mutation carriers 
(N=101) five years after test result disclosure 
 
Figure 2a: Preventive management strategies observed in BRCA1/2 mutation carriers < 40 
years (N=44) five years after test result disclosure 
Figure 2b: Preventive management strategies observed in BRCA1/2 mutation carriers ≥40 
years (N=57) five years after test result disclosure 
 
Figure 3: High perceptions of breast cancer risks before/after BRCA1/2 test result 
disclosure, depending on prophylactic surgery undergone during follow-up (N=246) 
 
Figure 4: High perceptions of ovarian cancer risks before/after BRCA1/2 test result 
disclosure, depending on prophylactic surgery undergone at follow-up (N=246) 
 
  
Figure 1: Preventive management strategies observed in BRCA1/2 mutation carriers (N=101) five 
years after test result disclosure  
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Figure 2a: Preventive management strategies observed in BRCA1/2 mutation carriers < 40 years 
(N=44) five years after test result disclosure  
 
 
Figure 2b: Preventive management strategies observed in BRCA1/2 mutation carriers ≥ 40 years 
(N=57) five years after test result disclosure  
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Figure 3: High perceptions of breast cancer risks before/after BRCA1/2 test result disclosure, 
depending on prophylactic surgery undergone during follow-up (N=246) 
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Figure 4: High perceptions of ovarian cancer risks before/after BRCA1/2 test result disclosure, 
depending on prophylactic surgery undergone at follow-up (N=246) 
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Table 1: Baseline medical and socio-demographic characteristics of study population 
(N= 246) 
 
 
 Carriers 
N=101 
Non carriers 
N=145 
 
 n % n % p* 
Having 1st. degree relatives with 
Breast Cancer (n= 218) 
0 
1 
>=2 
 
 
29 
50 
15 
 
 
30.9 
53.2 
16.0 
 
 
35 
57 
32 
 
 
 28.2 
46.0 
25.8 
 
 
 0.212 
 Having 1st. degree relatives with 
Ovarian Cancer (n= 220) 
0 
>=1 
 
 
58 
37 
 
 
61.1 
39.0 
 
 
73 
52 
  
 
58.4 
41.6 
 0.691 
Married (n=243) 
Yes 
No 
 
58 
41 
 
58.6 
41.4 
 
97 
47 
 
67.4 
32.6 
 0.162 
Educational background (n= 242) 
> High school 
<= High school 
 
59 
42 
 
58.4 
41.6 
 
74 
67 
  
52.5 
47.5 
0.360 
Children (n=220 ) 
Yes 
No 
 
67 
15 
 
81.7 
18.3 
 
110 
28 
  
79.7 
20.3 
0.718 
 
**: Chi2 test  
Proportions do not always add up to 100% because of rounding 
 
 
20/10/10 11:10  8944_3_table_74238_lxlh0d.doc 
 Page 2 sur 2 
Table 2:  Preventive strategies adopted by BRCA1/2 carriers and non carriers (all unaffected) five years after test result disclosure (N=246) 
 Carriers (N=101) Non-Carriers (N=145) 
Preventive strategies  age category age category 
Total <30 
n = 6 
30-39 
n=38  
40-49 
n=36  
≥50 
n=21 
Total < 30 
n=10  
30-39
n=32  
40-49 
n=44   
≥ 50 
n=59  
n (%) n (%)  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Bilateral Prophylactic Mastectomy  
After test result delivery   
 
 
7 (6.9) 
 
0 
 
2 (5.3) 
 
4 (11.1) 
 
1 (4.8) 
 
0 
 
0 
 
0 
 
0 
 
0 
Bilateral Prophylactic 
Oophorectomy  
Before test result delivery 
After test result delivery 
 
43 (42.6) 
 
2 
41 
0 7 (18.4) 
 
1 
6 
20 (55.6)
 
1 
19 
16 (76.2)
 
0 
16 
17 (11.7) 
 
14 
3 
0 0  3 (6.8) 
 
1 
2 
14 (23.7)
 
13 
1 
 m (SD)1 m (SD) 1 m (SD) 1 m (SD) 1 m (SD) 1 m (SD) 1 m (SD) m (SD) m (SD) m (SD)
Mammograms during the previous 
3 years* 
 
2.8 (1.4) 1.8 (2.3) 2.6 (1.4) 3.1 (1.4) 3.2 (1.1) 1.7 (1.2) 0.5 (1.3) 0.9 (1.0) 1.7 (1.1) 2.2 (1.1) 
MRI during the previous 3 years* 
 
1.7 (1.7) 1.5 (2.1) 1.5 (1.5) 2.2 (2.0) 1.2 (1.4) 0.1 (0.4) 0.2 (0.7) 0.0 (0.2) 0.1 (0.5) 0.1 (0.3) 
Ovarian ultrasound** 
Transvaginal US 
Abdominal US 
 
 
1.7 (1.7) 
0.6 (1.2) 
 
 
0.5 (1.2) 
0.7 (1.2) 
 
1.4 (1.7) 
0.8 (1.5) 
 
2.3 (1.6) 
0.2 (0.8) 
 
2.6 (2.3) 
0 (0) 
 
0.7 (1.4) 
0.4 (1.2) 
 
 
0.6 (1.9) 
0.1 (0.3) 
 
1.0 (1.6)
0.2 (0.8)
 
0.5 (1.3) 
0.8 (1.8) 
 
0.6 (1.1) 
0.3 (0.8) 
*: apart from RRM  **: apart from RRSO  
1  Mean number of investigations undergone during the last 3 years (means and standard deviations) 
 
